Practice parameter: pharmacologic treatment of spasticity in children and adolescents with cerebral palsy (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society.

ABSTRACT:

Objective

To evaluate published evidence of efficacy and safety of pharmacologic treatments for childhood spasticity due to cerebral palsy.

Methods

A multidisciplinary panel systematically reviewed relevant literature from 1966 to July 2008.

Results

For localized/segmental spasticity, botulinum toxin type A is established as an effective treatment to reduce spasticity in the upper and lower extremities. There is conflicting evidence regarding functional improvement. Botulinum toxin type A was found to be generally safe in children with cerebral palsy; however, the Food and Drug Administration is presently investigating isolated cases of generalized weakness resulting in poor outcomes. No studies that met criteria are available on the use of phenol, alcohol, or botulin

SUBMITTER: Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society 

PROVIDER: S-EPMC3122302 | biostudies-literature | 2010 Jan

REPOSITORIES: biostudies-literature